Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Stefano Molica, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Rosanna Mirabelli, MD, Giovanna Digiesi, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Fortunato Morabito, Manlio Ferrarini, MD

Blood (2008) 112 (11): 4187.

https://doi.org/10.1182/blood.V112.11.4187.4187

Published: 2008

Journal Articles

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2008) 112 (11): 4158.

https://doi.org/10.1182/blood.V112.11.4158.4158

Published: 2008

Journal Articles

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2007) 110 (11): 3093.

https://doi.org/10.1182/blood.V110.11.3093.3093

Published: 2007

Journal Articles

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2006) 108 (11): 2786.

https://doi.org/10.1182/blood.V108.11.2786.2786

Published: 2006

Journal Articles

Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression.

Stefano Molica, MD, Gaetano Vitelli, MD, Rosanna Mirabelli, MD, Giovanna Digiesu, MD, Diana Giannarelli, MD, Antonella Iorfida, PhD

Blood (2004) 104 (11): 4786.

https://doi.org/10.1182/blood.V104.11.4786.4786

Published: 2004

NARROW

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression.

Email alerts

ASH Publications

American Society of Hematology

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only